WO2011003357A1 - 用于肝或脾脏的核磁共振对比剂及其制备方法 - Google Patents

用于肝或脾脏的核磁共振对比剂及其制备方法 Download PDF

Info

Publication number
WO2011003357A1
WO2011003357A1 PCT/CN2010/075066 CN2010075066W WO2011003357A1 WO 2011003357 A1 WO2011003357 A1 WO 2011003357A1 CN 2010075066 W CN2010075066 W CN 2010075066W WO 2011003357 A1 WO2011003357 A1 WO 2011003357A1
Authority
WO
WIPO (PCT)
Prior art keywords
contrast agent
magnetic resonance
dtpa
nuclear magnetic
liver
Prior art date
Application number
PCT/CN2010/075066
Other languages
English (en)
French (fr)
Inventor
黄苏萍
周科朝
王维
李志友
Original Assignee
中南大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中南大学 filed Critical 中南大学
Publication of WO2011003357A1 publication Critical patent/WO2011003357A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface

Definitions

  • the invention relates to the field of medical materials, in particular to a liver- and spleen-specific positive nuclear magnetic resonance contrast agent and a preparation method thereof.
  • Tumor is one of the major diseases affecting human health in today's society.
  • a study published by the World Health Organization shows that the global cancer situation will become increasingly serious.
  • the number of new patients will increase from the current 10 million to 15 million in the next 20 years, and the number of deaths due to cancer will increase from 6 million to 1,000 per year.
  • 10,000, cancer has become the first fatal disease, of which the incidence of liver cancer ranks third in cancer. Every year, about 350,000 patients in China die from hepatitis B and liver cirrhosis, and they are increasing year by year.
  • Tumors, especially liver cancer are one of the main goals of current scientific researchers.
  • liver cancer is mainly based on surgical resection.
  • most tumor patients have been found in the advanced stage.
  • the three major therapies of Western medicine can also reduce or eliminate the tumor volume of patients with advanced tumors, it is difficult to prolong survival.
  • Chemotherapy and chemotherapy have serious toxic and side effects on immune function, hematopoietic function, and organs such as digestive system liver, kidney, heart and lung. Therefore, the overall conditions of chemoradiotherapy for patients with susceptibility to cancer have not improved, but have made it worse. Therefore, the cure rate of advanced liver cancer is not high, and the mortality rate is as high as 100%. Therefore, improving the accuracy of early diagnosis of liver cancer is the key to preventing the deterioration and death of cancer patients, thereby achieving the purpose of prolonging the life and even clinical cure of tumor patients.
  • Magnetic resonance imaging MRI has become an important means of early diagnosis of liver cancer due to its extremely fine tissue resolution. Contrast agent for magnetic resonance Imaging, MRICA) can significantly improve the contrast of different tissues, making the diseased tissue easy to be diagnosed and recognized, and can significantly improve the accuracy of early diagnosis of liver cancer.
  • MRICA is divided into two types, paramagnetic and superparamagnetic, according to its magnetization characteristics.
  • Superparamagnetic iron oxide contrast agent such as iron oxide nanoparticles
  • iron oxide nanoparticles because of the high toxicity of the magnetic nanoparticles to the human body, poor biocompatibility, making people adopt a certain biocompatible polymer or human serum Covering to reduce its toxicity to humans, but these contrast agents are not ideal for human blood compatibility.
  • magnetic resonance contrast agents with more applications in domestic hospitals are basically non-specific contrast agents (such as gadolinium (Gd). Because of its non-specific shortcomings, similar signal changes can be seen in all tissues after injection, which results in poor image contrast ratio, which greatly affects the accuracy of MRI diagnosis.
  • Gd gadolinium
  • the object of the present invention is to provide a liver- and spleen-specific positive nuclear magnetic resonance contrast agent and a preparation method thereof, so that the contrast agent has low toxicity, high stability, good biocompatibility and high sensitivity compared with the prior art. And high relaxation performance and liver and spleen specificity.
  • the object of the present invention is achieved in the following manner.
  • a liver- and spleen-specific positive nuclear magnetic resonance contrast agent is a composite particle coated with or grafted with Gd-DTPA on the surface of the HA particle, and the surface of the composite particle is also adsorbed with a modifier.
  • the modifier is human serum albumin, PEI or PEG.
  • the HA particles have a particle diameter of 1 to 100 nm, and the composite particles have a particle diameter of not more than 1000 nm.
  • the preparation method of the liver- and spleen-specific positive nuclear magnetic resonance contrast agent adding HA at a weight ratio of 0.1:1-20:1
  • the mixed reaction of Gd-DTPA was stirred for 12 hours, then washed, filtered, and dried to obtain HA-Gd-DTPA particles; and the NMR contrast agent was obtained by ultrasonically dispersing the modifier.
  • the weight ratio of HA to Gd-DTPA is preferably from 1:1 to 10:1.
  • the HA was first formulated into a 0.01 mol/L solution and mixed with Gd-DTPA.
  • the liver and spleen-specific positive nuclear magnetic resonance contrast agent also has a preparation method: Ca(NO 3 ) 2 and (NH 4 ) 2 HPO 4 are respectively formulated into 0.5 mol/L and 0.3 mol/ with 200 ml of deionized water.
  • the ultrasonic dispersion time of the above two methods was 30 min.
  • the modifiers all adopt human serum albumin, PEI or PEG. Add 0.001 - 0.05g of modifier per gram of HA.
  • the HA-Gd-DTPA nuclear magnetic resonance contrast agent prepared by the invention uses hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 , HA) as a bioceramic material similar in structure to bone and teeth. It has good biocompatibility, and the mice with acute toxicity have no death. The mice can be discharged from the kidney after the suspension of the nanoparticle suspension after injection of the HA nanoparticle suspension in the tail vein. There is no problem of aggregation in the body.
  • the invention solves the problems that the magnetic nanoparticles such as nano Fe 3 O 4 have high toxicity and poor biocompatibility to the human body, and are not easy to be solved in the body.
  • the HA-Gd-DTPA nuclear magnetic resonance contrast agent prepared by the invention has a HA nanoparticle suspension in the tail vein of the mouse, and it is found that there are HA nanoparticle distribution in the liver, spleen and other organs tissues, and the liver and spleen are mostly present.
  • Passive targeting characteristics; indicating that HA-Gd-DTPA NMR contrast agent has Hepatic and spleen specificity and high sensitivity and high relaxation properties solve other contrast agents (such as Gd-DTPA, Gd-DOTA) due to non-specificity.
  • Gd-DTPA Gd-DOTA
  • the HA-Gd-DTPA nuclear magnetic resonance contrast agent prepared by the invention has good dispersion stability after being modified by human serum albumin, PEI, PEG, etc., and solves the problem of particle agglomeration.
  • the problem of death caused by the injection of contrast agent in animals improves the development of HA-Gd-DTPA and its clinical application.
  • Figure 1 is a process flow diagram of the present invention
  • Figure 2 is a flow chart of another process of the present invention.
  • Figure 3 is a MIR chart of different Gd-DTPA content HA-Gd-DTPA
  • the content corresponding from left to right is 1.25%, 2.5%, 5%.
  • Figure 4 is a HA-Gd-DTPA MIR scan of different modifiers
  • the modifiers from left to right are human serum albumin, PEI, PEG.
  • Figure 5 is a MIR chart of different contrast agents injected into rats
  • rats From left to right are rats (conventional control), rats (common contrast agents), and rats (HA-Gd-DTPA).
  • Figure 6 is a scan of the MIR T1 sequence of HA-Gd-DTPA contrast agent in SD rats;
  • each column is scanned in three directions of front, left side and right side.
  • HA is formulated into a 0.01 mol/L solution
  • PEI per gram of HA Add 0.001 - 0.05g
  • DTPA contrast agent the physiological response of rats was observed for a period of time.
  • the liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.
  • HA is formulated into a 0.01 mol/L solution
  • the liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.
  • HA is formulated into a 0.01 mol/L solution
  • the liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.
  • HA is formulated into a 0.01 mol/L solution
  • DTPA contrast agent the physiological response of rats was observed for a period of time.
  • the liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.
  • Ca(NO 3 ) 2 and (NH 4 ) 2 HPO 4 were separately prepared into 0.5 mol/L and 0.3 mol/L aqueous solutions with 200 ml of deionized water, and the (NH 4 ) 2 HPO 4 solution was dropped into Ca with a dropper.
  • the (NO 3 ) 2 solution 5 g of GD-DTPA (converted according to the concentration of GD-DTPA injection) was added, and the pH was adjusted to 11 to 12 with NH 4 OH throughout the process. After stirring for 24 hours, it was poured into an autoclave for hydrothermal synthesis, and the temperature was set to 160 ° C, and the holding time was 1 h. After washing, filtering and drying, HA-Gd-DTPA particles are obtained.
  • HA-Gd-DTPA 0.1 g of HA-Gd-DTPA is weighed into 100 ml of water, and a dispersing agent PEI (0.001 - 0.05 g per gram of HA) is added, and ultrasonically dispersed for 30 minutes.
  • the solution was subjected to magnetic resonance scanning to measure the respective signal intensity.
  • Three SD rats of equal weight were used for routine control (001) and HA-Gd-DTPA contrast agent for tail vein injection. The physiological response of the rats was observed for a period of time.
  • the liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.
  • Ca(NO 3 ) 2 and (NH 4 ) 2 HPO 4 were separately prepared into 0.5 mol/L and 0.3 mol/L aqueous solutions with 200 ml of deionized water, and the (NH 4 ) 2 HPO 4 solution was dropped into Ca with a dropper.
  • the (NO 3 ) 2 solution 5 g of GD-DTPA (converted according to the concentration of GD-DTPA injection) was added, and the pH was adjusted to 11 to 12 with NH 4 OH throughout the process. After stirring for 24 hours, it was poured into an autoclave for hydrothermal synthesis, and the temperature was set to 160 ° C, and the holding time was 1 h.
  • HA-Gd-DTPA particles were obtained, 0.1 g of HA-Gd-DTPA was weighed into 100 ml of water, and dispersant human serum albumin (0.001 - 0.05 g per gram of HA) was added and ultrasonically dispersed. At 30 min, the obtained solutions were subjected to magnetic resonance scanning to measure the respective signal intensities. Three SD rats of equal weight were used for routine control (001), tail vein injection of HA-Gd-DTPA contrast agent, and rats for a period of time. Physiological response. The liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.
  • Ca(NO 3 ) 2 and (NH 4 ) 2 HPO 4 were separately prepared into 0.5 mol/L and 0.3 mol/L aqueous solutions with 200 ml of deionized water, and the (NH 4 ) 2 HPO 4 solution was dropped into Ca with a dropper.
  • the (NO 3 ) 2 solution 5 g of GD-DTPA (converted according to the concentration of GD-DTPA injection) was added, and the pH was adjusted to 11 to 12 with NH 4 OH throughout the process. After stirring for 24 hours, it was poured into an autoclave for hydrothermal synthesis, and the temperature was set to 160 ° C, and the holding time was 1 h. After washing, filtering and drying, HA-Gd-DTPA particles were obtained.
  • HA-Gd-DTPA 0.1 g was weighed into 100 ml of water, and a dispersing agent PEG (0.001 - 0.05 g per gram of HA) was added, and ultrasonically dispersed for 30 minutes. The solution was subjected to magnetic resonance scanning to measure the respective signal intensity. Three SD rats of equal weight were used for routine control (001) and HA-Gd-DTPA contrast agent for tail vein injection. The physiological response of the rats was observed for a period of time. The liver cells were subjected to nuclear magnetic resonance scanning under the MIR T1 sequence.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

[根据细则37.2由ISA制定的发明名称]　 用于肝或脾脏的核磁共振对比剂及其制备方法 技术领域
本发明涉及医学材料领域，尤其是一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法。
背景技术
肿瘤是当今社会影响人类健康的主要疾病之一。世界卫生组织发表的一项研究报告表明，全球癌症状况将日益严重，今后20年新患者人数将由目前的每年1000万增加到1500万，因癌症而死亡的人数也将由每年600万增至1000 万，癌症已成为第一位致死疾病，其中肝癌的发病率居癌症第三位，每年中国约有35万患者死于乙型肝炎、肝硬化导致的肝癌，且呈逐年上升趋势，因此攻克治疗肿瘤，特别是肝癌是目前科学研究者们的主要目标之一。
目前 肝癌的治疗主要以手术切除为首选， 但多数肿瘤患者被发现时已处于中晚期。尽管西医的三大疗法也可以使中晚期肿瘤病人的肿瘤体积缩小或消失，但很难延长生存期。而放化疗对免疫功能、造血功能以及消化系统肝肾心肺等器官具有严重的毒副作用。所以放化疗对于易发性的肿瘤患者的整体条件不但没有改善，反而促使其更恶化了。所以中晚期肝癌的治愈率不高，死亡率高达100%。因此提高肝癌的早期诊断的准确率，是防止肿瘤患者恶化及死亡，从而达到延长肿瘤患者生命、甚至临床治愈的目的的关键。
磁共振成像（magnetic resonance imaging, MRI）因其具有极精细的组织分辨率，已成为早期影像诊断肝癌的重要手段。磁共振对比剂（contrast agent for magnetic resonance imaging,MRICA）能显著提高不同组织的对比度，使病变组织容易被诊断和识别，能显著提高肝癌早期诊断的准确率。MRICA按磁化特性，人们常将其分为顺磁性和超顺磁性两种类型。
超顺磁性氧化铁对比剂（如氧化铁纳米颗粒），由于该磁性纳米粒子对人体具有较高的毒性，生物相容性差，使得人们采用具有一定生物相容性的聚合物或人血清百蛋白进行包覆，以降低其对人体的毒性，但这些对比剂与人体血液相容性并不理想。
目前国内医院应用较多的磁共振对比剂基本上为非特异性对比剂（如钆（ Gd ）的螯合物），由于其非特异性缺点，患者注射后各组织均可见类似信号改变，从而造成图像对比率差，大大影响了 MRI 诊断准确率。
 技术问题
本发明的目的是提供一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法，使得对比剂与现有技术相比具有低毒、高稳定性、好的生物相容性、高敏感性和高弛豫性能以及肝、脾脏特异性。
技术解决方案
本发明的目的是通过以下方式实现的。
一种肝、脾脏特异性阳性核磁共振对比剂是在HA粒子表面包覆或枝接有Gd-DTPA的复合颗粒，所述的复合颗粒表面还吸附了修饰剂, 所述的修饰剂为人血清白蛋白、PEI或PEG。
所述的HA 粒子粒径为1-100nm，所述的复合颗粒粒径不高于1000nm。
所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法：以重量比 0.1 ：1-20：1添加 HA 和 Gd-DTPA 混合反应，搅拌12小时后， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒；加修饰剂 超声分散后得到所述的 核磁共振对比剂 。
HA 与Gd-DTPA的重量比优选为1：1-10：1。
先将HA配成0.01 mol/L 的溶液，再与Gd-DTPA 混合反应 。
所述的肝、脾脏特异性阳性核磁共振对比剂还有一种制备方法： 分别将 Ca(NO3)2 和 (NH4)2HPO4 用 200ml 去离子水配制成 0.5mol/L 和 0.3mol/L 的水溶液 ，将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，再加入5g Gd-DTPA ，用氨水调节pH 11 ～12 ，搅拌24h后倒入高压釜中，在160℃，保温时间为1h，进行水热合成，再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒；加修饰剂 超声分散后得到所述的 核磁共振对比剂。
上述两种方法超声分散时间均为30min。 所述的修饰剂均采用人血清白蛋白、PEI或PEG， 每克HA中添加0.001 - 0.05g 修饰剂 。
 有益效果
本发明制备的HA-Gd-DTPA核磁共振对比剂，所采用的羟基磷灰石（Ca10 (PO4 )6 (OH)2，HA）是一种结构与骨和牙齿相似的生物陶瓷材料，具有良好的生物相容性，急性毒性动物实验结果小鼠无一死亡；小鼠尾静脉注射HA纳米颗粒悬液后纳米颗粒悬液后可从肾脏排出。不存在体内聚集的问题。 解决了纳米Fe3O4等 磁性纳米粒子对人体具有较高毒性和生物相容性差， 在体内不易排解等问题。
本发明制备的HA-Gd-DTPA核磁共振对比剂，小鼠尾静脉注射HA纳米颗粒悬液后发现在肝、脾等器官组织均有HA纳米颗粒分布，其中以肝、脾居多，呈现一种被动靶向特点；说明HA-Gd-DTPA核磁共振对比剂具有 肝、脾 脏特异性及高敏感性和高弛豫性能，解决了其他对比剂（如 Gd-DTPA 、Gd-DOTA） 由于 无特异性， 生物学分布没有专一性，无特殊器官靶向性等原因造成的正常肝组织与病变组织的 MRI 对比度差，MRI诊断准确率低 等缺点。
本发明制备的HA-Gd-DTPA核磁共振对比剂，经人血清白蛋白、PEI、PEG等进行修饰后，具有良好的分散稳定性，解决了由于颗粒团聚 导致动物在注射对比剂后致使死亡的问题，提高了 HA-Gd-DTPA 的显影效果及其在临床中的应用。
 附图说明
图1为本发明的工艺流程图；
图2为本发明的另一工艺流程图；
图3为不同Gd-DTPA含量HA-Gd-DTPA的MIR图；
从左至右对应的含量为 1.25% ， 2.5% ， 5% 。
图4为 不同修饰剂的 HA-Gd-DTPA MIR 扫描图；
从左至右对应的 修饰剂为 人血清白蛋白，PEI，PEG。
图5为 大鼠体内注射不同对比剂的MIR图；
从左至右依次为大鼠（常规对照）、大鼠（常用对比剂）、大鼠（ HA-Gd-DTPA ）。
图6为 HA-Gd-DTPA 对比剂在SD大鼠体内MIR T1序列扫描图；
从左至右对应的为 常规对照， 5% Gd-DTPA 的 对比剂 1ml, 5% Gd-DTPA 的 对比剂 10ml, 每一列为正面、左侧面、右侧面三个方向扫描图。
 本发明的最佳实施方式
本发明的实施方式
实施例1
称取0.1mol Ca(NO3)2 和0.06 mol (NH4)2HPO4于烧杯中，分别加300ml蒸馏水配成溶液并搅拌均匀，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，整个过程中用NH4OH调节pH保持在 11 ～12 。待反应完全后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。再经清洗、过滤、干燥得到羟基磷灰石纳米颗粒；将HA配成0.01 mol/L 的溶液，在磁力搅拌下以重量比HA： Gd-DTPA=1 ：1 加入 钆喷酸葡胺 （根据GD-DTPA注射液浓度换算），继续搅拌12小时后， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入分散剂PEI（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例2
称取0.1mol Ca(NO3)2 和0.06 mol (NH4)2HPO4于烧杯中，分别加300ml蒸馏水配成溶液并搅拌均匀，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，整个过程中用NH4OH调节pH保持在 11 ～12 。待反应完全后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。再经清洗、过滤、干燥得到羟基磷灰石纳米颗粒；将HA配成0.01 mol/L 的溶液，在磁力搅拌下以重量比HA： Gd-DTPA=10 ：1 加入GD-DTPA（根据GD-DTPA注射液浓度换算），继续搅拌12小时后，再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入分散剂PEI（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例3
称取0.1mol Ca(NO3)2 和0.06 mol (NH4)2HPO4于烧杯中，分别加300ml蒸馏水配成溶液并搅拌均匀，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，整个过程中用NH4OH调节pH保持在 11 ～12 。待反应完全后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。再经清洗、过滤、干燥得到羟基磷灰石纳米颗粒；将HA配成0.01 mol/L 的溶液，在磁力搅拌下以重量比HA： Gd-DTPA=20：1加入GD-DTPA（根据GD-DTPA注射液浓度换算），继续搅拌12小时后， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入PEI （每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例4
称取0.1mol Ca(NO3)2 和0.06 mol (NH4)2HPO4于烧杯中，分别加300ml蒸馏水配成溶液并搅拌均匀，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，整个过程中用NH4OH调节pH保持在 11 ～12 。待反应完全后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h 。再经清洗、过滤、干燥得到羟基磷灰石纳米颗粒；将HA配成0.01 mol/L 的溶液，在磁力搅拌下以重量比HA： Gd-DTPA=0.1 ：1 加入GD-DTPA（根据GD-DTPA注射液浓度换算），继续搅拌12小时后，再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入PEI （每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例5
称取0.1mol Ca(NO3)2 和0.06 mol (NH4)2HPO4于烧杯中，分别加300ml蒸馏水配成溶液并搅拌均匀，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，整个过程中用NH4OH调节pH保持在 11 ～12 。待反应完全后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。 再经清洗、过滤、干燥得到羟基磷灰石纳米颗粒；将HA配成0.01 mol/L 的溶液，在磁力搅拌下以重量比HA： Gd-DTPA=1 ：1 加入GD-DTPA（根据GD-DTPA注射液浓度换算），继续搅拌12小时后， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入 分散剂人血清白蛋白（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例6
称取0.1mol Ca(NO3)2 和0.06 mol (NH4)2HPO4于烧杯中，分别加300ml蒸馏水配成溶液并搅拌均匀，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，整个过程中用NH4OH调节pH保持在 11 ～12 。待反应完全后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。 再经清洗、过滤、干燥得到羟基磷灰石纳米颗粒；将HA配成0.01 mol/L 的溶液，在磁力搅拌下以重量比HA： Gd-DTPA=1 ：1 加入GD-DTPA（根据GD-DTPA注射液浓度换算），继续搅拌12小时后， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入 分散剂PEG（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例7
以重量比HA： Gd-DTPA=5 ：1 加入 钆喷酸葡胺 （根据GD-DTPA注射液浓度换算），其余步骤和条件与实施例1相同。
实施例8
分别将 Ca(NO3)2 和 (NH4)2HPO4 用 200ml 去离子水配制成 0.5mol/L 和 0.3mol/L 的水溶液 ，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，再加入5gGD-DTPA（根据GD-DTPA注射液浓度换算），整个过程中用NH4OH调节pH保持在 11 ～12 。搅拌24h后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入 分散剂PEI（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例9
分别将 Ca(NO3)2 和 (NH4)2HPO4 用 200ml 去离子水配制成 0.5mol/L 和 0.3mol/L 的水溶液 ，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，再加入5gGD-DTPA（根据GD-DTPA注射液浓度换算），整个过程中用NH4OH调节pH保持在 11 ～12 。搅拌24h后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入 分散剂人血清白蛋白（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
实施例10
分别将 Ca(NO3)2 和 (NH4)2HPO4 用 200ml 去离子水配制成 0.5mol/L 和 0.3mol/L 的水溶液 ，用滴管将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，再加入5gGD-DTPA（根据GD-DTPA注射液浓度换算），整个过程中用NH4OH调节pH保持在 11 ～12 。搅拌24h后倒入高压釜中进行水热合成，设定温度160℃，保温时间为1h。 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒，称取0.1gHA-Gd-DTPA放入100ml水中，加入 分散剂PEG（每克HA中添加0.001 - 0.05g ），并超声分散30min，所得溶液进行磁共振下扫描测各自信号强度，取3只等重同种SD大鼠，分别进行常规对照(001),尾静脉注射HA- Gd-DTPA 对比剂 , 一段时间观察大鼠的生理反应。并对其肝脏细胞在MIR T1序列下进行核磁共振扫描。
 工业实用性
序列表自由内容

Claims (1)

  1. 1 、一种肝、脾脏 特异性阳性核磁共振对比剂，其特征在于，所述的对比剂是在HA粒子表面包覆或枝接有Gd-DTPA的复合颗粒，所述的复合颗粒表面还吸附了修饰剂；所述的修饰剂为人血清白蛋白、PEI或PEG。
    2 、根据权利要求1所述的肝、脾脏特异性阳性核磁共振对比剂，其特征在于，所述的HA 粒子粒径为1-100nm，所述的复合颗粒粒径不高于1000nm。
    3 、权利要求1所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，以重量比 0.1 ：1-20：1添加 HA 和 Gd-DTPA 混合反应， 搅拌12小时后， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒；加修饰剂 超声分散后得到所述的 核磁共振对比剂 。
    4 、根据权利要求3所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，HA与Gd-DTPA的重量比为1：1-10：1。
    5 、根据权利要求3或4所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，先将HA配成0.01 mol/L 的溶液，再与 Gd-DTPA 混合反应 。
    6 、根据权利要求3所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，超声分散时间为30min。
    7 、根据权利要求3所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，所述的修饰剂为人血清白蛋白、PEI或PEG， 每克HA中添加0.001 - 0.05g 修饰剂 。
    8 、权利要求1所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于， 分别将 Ca(NO3)2 和 (NH4)2HPO4 用 200ml 去离子水配制成 0.5mol/L 和 0.3mol/L 的水溶液 ，将(NH4)2HPO4溶液滴入Ca(NO3)2溶液中，再加入5g Gd-DTPA ， 用氨水调节pH 11 ～12 ，搅拌24h后倒入高压釜中，在160℃，保温时间为1h，进行水热合成， 再经清洗、过滤、干燥得到HA-Gd-DTPA颗粒；加修饰剂 超声分散后得到所述的 核磁共振对比剂。
    9 、根据权利要求8所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，超声分散时间为30min。
    10 、根据权利要求8所述的肝、脾脏特异性阳性核磁共振对比剂的制备方法，其特征在于，所述的修饰剂为人血清白蛋白、PEI或PEG， 每克HA中添加0.001 - 0.05g 修饰剂 。
PCT/CN2010/075066 2009-05-13 2010-07-08 用于肝或脾脏的核磁共振对比剂及其制备方法 WO2011003357A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009100433844A CN101549161B (zh) 2009-05-13 2009-05-13 一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法
CN200910043384.4 2009-05-13

Publications (1)

Publication Number Publication Date
WO2011003357A1 true WO2011003357A1 (zh) 2011-01-13

Family

ID=41153799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/075066 WO2011003357A1 (zh) 2009-05-13 2010-07-08 用于肝或脾脏的核磁共振对比剂及其制备方法

Country Status (2)

Country Link
CN (1) CN101549161B (zh)
WO (1) WO2011003357A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549161B (zh) * 2009-05-13 2010-12-01 中南大学 一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法
CN101862461B (zh) * 2010-06-18 2012-01-04 上海纳米技术及应用国家工程研究中心有限公司 用于淋巴系统特异成像的含钆大分子造影剂及其制备方法
CN102397564B (zh) * 2010-09-19 2013-05-29 复旦大学 一种肿瘤靶向诊断核磁共振造影剂及其制备方法
CN101979097A (zh) * 2010-10-20 2011-02-23 华东理工大学 一种含钆磁共振造影剂及其制备方法
CN103894557B (zh) * 2014-03-19 2016-01-20 丽水市中心医院 磁共振成像下可视的功能化金纳米粒子的制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867963A (en) * 1987-01-29 1989-09-19 Temple University Of The Commonwealth System Of Higher Education Enhancement of NMR imaging of tissue by paramagnetic pyrophosphate contrast agent
WO1999055230A1 (en) * 1998-04-28 1999-11-04 Jagotec Ag Hyaluronan-based imaging agents
CN1397348A (zh) * 1995-06-07 2003-02-19 ImaRx药物公司 用于诊断和治疗的新的靶向组合物
WO2007141537A1 (en) * 2006-06-07 2007-12-13 Apatech Limited Biomedical materials
CN101549161A (zh) * 2009-05-13 2009-10-07 中南大学 一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867963A (en) * 1987-01-29 1989-09-19 Temple University Of The Commonwealth System Of Higher Education Enhancement of NMR imaging of tissue by paramagnetic pyrophosphate contrast agent
CN1397348A (zh) * 1995-06-07 2003-02-19 ImaRx药物公司 用于诊断和治疗的新的靶向组合物
WO1999055230A1 (en) * 1998-04-28 1999-11-04 Jagotec Ag Hyaluronan-based imaging agents
WO2007141537A1 (en) * 2006-06-07 2007-12-13 Apatech Limited Biomedical materials
CN101549161A (zh) * 2009-05-13 2009-10-07 中南大学 一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法

Also Published As

Publication number Publication date
CN101549161B (zh) 2010-12-01
CN101549161A (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
Shokouhimehr et al. Biocompatible Prussian blue nanoparticles: Preparation, stability, cytotoxicity, and potential use as an MRI contrast agent
US4770183A (en) Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
WO2011003357A1 (zh) 用于肝或脾脏的核磁共振对比剂及其制备方法
Sulek et al. Peptide functionalized superparamagnetic iron oxide nanoparticles as MRI contrast agents
Hu et al. Facile synthesis of hyaluronic acid-modified Fe 3 O 4/Au composite nanoparticles for targeted dual mode MR/CT imaging of tumors
CN108324962B (zh) 一种团簇结构的四氧化三铁纳米颗粒的制备方法
CN104758955B (zh) 一种拥有多重刺激药物释放以及mri造影能力的超分子胶囊的制备方法
CN101912623B (zh) 具有靶向功能铁-钆双模式磁共振造影剂的制备及应用
JPH03503612A (ja) 磁気共鳴イメージングに関する改良
CN103143043B (zh) 一种Fe3O4/Au复合纳米颗粒的制备方法
CN104436220B (zh) 一种壳聚糖磁性纳米微球的制备方法及其用途
CN103463648A (zh) 一种表面修饰的氧化铁核-氧化钆壳复合纳米粒子及其制法和用途
CN103041407A (zh) 核-壳型纳米造影剂、其制备方法及应用
CN103041408A (zh) 核-壳型纳米造影剂、其制备方法及应用
Zheng et al. Recent progress of molecular imaging probes based on gadofullerenes
CN101474414B (zh) 高分子包裹磁性纳米粒子造影剂的制备及应用
CN107343961A (zh) 一种基于rgd多肽修饰的超支化聚乙烯亚胺纳米探针的制备方法
CN106668878A (zh) 一种集t1、t2双模式为一体的多功能介孔碳小球及其制备方法
Li et al. A pH-responsive magnetic resonance tuning probe for precise imaging of bacterial infection in vivo
CN110559453B (zh) 一种用于显像指导的磁性纳米颗粒及其制备方法
CN111281984B (zh) 基于表面修饰的四氧化三铁磁性纳米探针及其制备和应用
WO2011122770A9 (ko) 만노스가 말단 수식된 고분자가 코팅된 자기공명 영상 조영제 및 그것의 제조 방법
Wang et al. Using PEGylated iron oxide nanoparticles with ultrahigh relaxivity for MR imaging of an orthotopic model of human hepatocellular carcinoma
CN109675061A (zh) 纳米材料及其制备方法和应用
CN112516334B (zh) 一种edtmp修饰的四氧化三铁纳米颗粒及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10796734

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10796734

Country of ref document: EP

Kind code of ref document: A1